RECURRENT ACUTE MYELOID LEUKEMIA

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to fi…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This early-phase trial tests a new drug called M3814 alongside three chemotherapy drugs (mitoxantrone, etoposide, and cytarabine) in 48 adults with acute myeloid leukemia that has returned or not responded to treatment. The main goal is to find the safest dose and understand side…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant in adults with acute myeloid leukemia that has returned or not responded to treatment. The goal is to find the safest dose of sorafenib and …

This early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer c…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted drug (quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo helps control the cancer. About 52…

This phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combo is …

This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.

This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if the combination can shrink or control the cancer. Participants will take the drugs by mout…

This early-phase trial tests a combination of two drugs—entrectinib and ASTX727—in people with a specific, hard-to-treat form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study aims to find the safest dose and watch for side effects in 13 a…

This early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…

This early-phase study tests a three-drug combination (navitoclax, venetoclax, and decitabine) in adults and teens with acute myeloid leukemia that returned or didn't respond to previous treatment. The goal is to find the safest dose and see if the combo can shrink or control the…

This early-phase study tests a drug called palbociclib, given alone or with other medicines, in people whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand side effects. About 32 adults with acute myeloi…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This study looks at a drug called enasidenib for children and teens with acute myeloid leukemia (AML) that has come back or is hard to treat. The drug targets a specific genetic change (IDH2 mutation) found in their cancer cells. The main goals are to check the drug's safety and …

This early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …

This early-phase trial tests whether adding regorafenib to the standard venetoclax and azacitidine regimen is safe and effective for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 adults will receive the three-drug combina…

This early-phase study looks at how the immune system responds to leukemia tumors after low-dose radiation given as part of standard care. Ten adults with new or recurrent myeloid leukemia will have their immune responses measured. The goal is to learn whether adding immunotherap…